Tag

Mash

All articles tagged with #mash

Alan Alda Frames Parkinson's as a 'Hobby' in CBS Interview
health-and-entertainment9 days ago

Alan Alda Frames Parkinson's as a 'Hobby' in CBS Interview

Actor Alan Alda, 90, discussed his Parkinson's diagnosis and his use of humor to manage the condition in a CBS News interview. He revealed that his first symptom was acting out dreams, which occurred when he was 79. Alda emphasized that he does not let the disease define him, calling it a 'hobby' rather than his identity. He also highlighted the importance of human connection, a value he cultivated during his time on 'M*A*S*H' and now promotes through his podcast and the Alan Alda Center for Communicating Science.

MASH Unraveled: Molecular Drivers of Steatohepatitis and Cancer Risk in MASLD
science1 month ago

MASH Unraveled: Molecular Drivers of Steatohepatitis and Cancer Risk in MASLD

This Nature review outlines how MASLD progresses to MASH through insulin resistance, lipid dysregulation and lipotoxicity, genetic risk variants (e.g., PNPLA3, TM6SF2, HSD17B13), adipose–immune dysfunction, fibrogenesis and gut–liver axis disturbances; it highlights progression to fibrosis, cirrhosis and hepatocellular carcinoma, and notes advances in polygenic risk scores and targeted therapies addressing lipogenesis, mitochondrial metabolism and bile acid signaling, underscoring MASLD/MASH as a multi‑organ disease with translational therapeutic potential.

Precision moves in MASH: a new era of tailored therapies
health1 month ago

Precision moves in MASH: a new era of tailored therapies

This Nature review maps the current and future treatment landscape for metabolic dysfunction‑associated steatohepatitis (MASH), noting that recent approvals (resmetirom and semaglutide) mark an inflection point for non‑cirrhotic disease and fibrosis. It highlights MASH heterogeneity with liver‑centric and cardiometabolic subsets, arguing that optimal therapy will need stratified or combinatorial approaches that target metabolic dysfunction, fibrogenesis, inflammation, and the gut–liver axis, alongside lifestyle modification. Advances in disease phenotyping and biomarkers are seen as enabling a shift toward personalized, mechanism‑driven therapy.

Reluctant Spark: How M*A*S*H’s Larry Gelbart Helped Create Three's Company
entertainment2 months ago

Reluctant Spark: How M*A*S*H’s Larry Gelbart Helped Create Three's Company

M*A*S*H co-creator Larry Gelbart, burned out after four years on the show, reluctantly agreed in the mid-70s to develop ABC’s Three's Company; he was wary of turning his follow-up into a 'bedroom farce' and criticized diluting the British original, demanding $50,000 for a half-hour pilot. ABC hired him but ultimately rewrote the pilot and recast the leads; Gelbart still earned his fee and royalties, while the resulting series went on to become one of the most beloved sitcoms of the 1980s despite mixed early reviews of the pilot.

DT-109 Reverses Severe Fatty Liver Disease by Repairing the Gut Barrier
health-and-medicine3 months ago

DT-109 Reverses Severe Fatty Liver Disease by Repairing the Gut Barrier

An experimental glycine-based tripeptide called DT-109 reversed severe metabolic dysfunction–associated steatohepatitis (MASH) in animal studies by strengthening the gut barrier and lowering intestinal ammonia, disrupting the harmful gut-to-liver inflammatory loop; findings in mice and nonhuman primates point to a new gut-targeted therapy approach for MASH, with clinical trials needed to assess safety and effectiveness in people.

Alan Alda Hates the Crying Moment That Redefined M*A*S*H
entertainment3 months ago

Alan Alda Hates the Crying Moment That Redefined M*A*S*H

Alan Alda reflects on the Season 1 moment from MASH in the episode Sometimes You Hear the Bullet, where Hawkeye loses a friend on the operating table and is comforted by Col. Henry Blake. He says he dislikes his crying performance in that shot, feeling he overacted, even as the scene is recognized as a turning point that fused tragedy with humor and helped push the series toward its dramatic legacy.

McLean Stevenson Departed M*A*S*H for Top Billing, Changing the Show's Arc
entertainment4 months ago

McLean Stevenson Departed M*A*S*H for Top Billing, Changing the Show's Arc

Stevenson quit M*A*S*H after three seasons, citing a desire for center-stage status and telling TV Guide he wanted to be “one of one” as Hawkeye became the series’ focal point. Co-creators Gelbart and Reynolds crafted Henry Blake’s death as a farewell that underscored war’s cold reality. Stevenson later regretted leaving, and his post‑M*A*S*H projects—The McLean Stevenson Show and Hello, Larry—failed to reach the show’s earlier success, cementing the exit as one of TV’s most infamous.

Formoterol Reverses Fatty Liver Damage, Sparking Clinical Trials
health4 months ago

Formoterol Reverses Fatty Liver Damage, Sparking Clinical Trials

A decades-old asthma drug, formoterol, reversed fatty liver damage in mice modeling MASH and showed associations with fewer severe liver complications in people taking beta-2 agonists; MUSC researchers are moving to human trials to test whether the drug can treat MASH and diabetic kidney disease by boosting beta-2 signaling and mitochondrial biogenesis, though causal proof in humans is not yet established.

Gwen Farrell Adair, M*A*S*H Nurse and Trailblazer, Dies at 94
obituaries5 months ago

Gwen Farrell Adair, M*A*S*H Nurse and Trailblazer, Dies at 94

Gwen Farrell Adair, the versatile actress who played multiple nurses on M*A*S*H, died of natural causes at age 94 in Sherman Oaks. Born in Austin, Texas, she appeared on M*A*S*H from its 1972 debut through its 1983 run, and also acted in Starsky & Hutch and films such as Black Gunn, Soylent Green, Coffy, Earthquake, Towering Inferno, and Billy Jack Goes to Washington. Beyond acting, she managed Los Angeles boxers, became the first female licensed referee in 1979, and owned a Fatburger franchise. Her family described her as a guiding light and scheduled GoFundMe arrangements for funeral expenses.

Vitamin B3 Shows Promise as a Safe, Cost-Effective Treatment for Fatty Liver Disease
health1 year ago

Vitamin B3 Shows Promise as a Safe, Cost-Effective Treatment for Fatty Liver Disease

Scientists at UC San Diego have developed an investigational drug, ION224, that targets the root cause of severe fatty liver disease (MASH) by inhibiting the enzyme DGAT2, showing promising results in a Phase IIb trial with significant liver health improvements and no serious side effects, offering hope for a potential new treatment to halt or reverse disease progression.